Implications of recent hypertension trials for the generalist physician: whom do we treat, and how?
Abstract The publication china glaze fairytale bliss of the results of the Swedish Trial in Old Patients with Hypertension-2 (STOP-2) and the termination of the doxazocin arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) study again raise the question of whether all antihypertensives deliver equal cardiovascu